Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences GILD, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable options, 10 are puts, totaling $379,607, and 2 are calls, amounting to $54,775.
Predicted Price Range
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $65.0 to $92.5 for Gilead Sciences over the last 3 months.
Insights into Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Gilead Sciences's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Gilead Sciences's whale activity within a strike price range from $65.0 to $92.5 in the last 30 days.
Gilead Sciences Option Activity Analysis: Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|
| GILD | PUT | SWEEP | NEUTRAL | 01/19/24 | $70.00 | $68.1K | 5.6K | 130 |
| GILD | PUT | SWEEP | NEUTRAL | 01/17/25 | $87.50 | $41.5K | 183 | 0 |
| GILD | PUT | SWEEP | NEUTRAL | 01/19/24 | $80.00 | $41.3K | 2.5K | 0 |
| GILD | PUT | SWEEP | BULLISH | 01/17/25 | $87.50 | $38.4K | 183 | 81 |
| GILD | PUT | SWEEP | BULLISH | 01/17/25 | $92.50 | $37.1K | 24 | 71 |
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Present Market Standing of Gilead Sciences
- Trading volume stands at 4,329,152, with GILD's price down by -0.45%, positioned at $77.55.
- RSI indicators show the stock to be is currently neutral between overbought and oversold.
- Earnings announcement expected in 84 days.
What The Experts Say On Gilead Sciences
In the last month, 1 experts released ratings on this stock with an average target price of $75.0.
- An analyst from Deutsche Bank downgraded its action to Hold with a price target of $75.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Gilead Sciences, Benzinga Pro gives you real-time options trades alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
